X-linked Moesin Associated Immunodeficiency

Plain-language summary

This is a retrospective genetic study of male patients with X-linked immunodeficiency associated with a mutation in the MOESIN gene (MSN). It enrolls male patients who carry a mutation in the MSN gene and do not object to the collection of their personal health data. The study does not use a phase designation and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Intervention

genetic restrospective study

Start date

8/12/2021

Estimated completion

1/12/2027

Countries

United States, Australia, Belgium, France, Japan, Netherlands

Related genes

Locations

• Bethesda, United States
• Philadelphia, United States
• Providence, United States
• Brisbane, Australia
• Brussels, Belgium
• Paris, France
• Rennes, France
• Saint-Etienne, France
• Bunkyō City, Japan
• Rotterdam, Netherlands

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male patient with a mutation in the MOESIN gene (MSN)
* No objection to the collection of personal health data

Exclusion Criteria:

\-